Answers are grounded in this paper and cite their sources.
The open-source software movement has successfully pioneered several strategies that might also be applicable in drug discovery and development. Munos considers the challenges involved, and proposes a model to harness the potential of open-source drug R&D. The low number of novel therapeutics approved by the US FDA in recent years continues to cause great concern about productivity and declining innovation. Can open-source drug research and development, using principles pioneered by the highly successful open-source software movement, help revive the industry?
No takes yet. Share an insight, caveat, or question.
Bernard Munos (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: